Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 155 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Why the Bone Marrow Registry Needs More Diverse Donors and How... March 30, 2021 Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed... December 21, 2023 Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’... December 12, 2021 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Load more HOT NEWS What Is Scanxiety? How People With Cancer and Survivors Can Cope ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and... Foodie Fridays-Gazpacho: A Favorite Summer Soup When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic...
